Connecting@LABORAMA 2023

After the success of last year, our event Connecting@LABORAMA will take place in 2023 as well. This exclusive networking event is for all members exhibiting at LABORAMA 2023. Members/exhibitors will have an additional opportunity to invite decision-makers to the fair.

The programme:

  • Invite your decision-makers in the afternoon of March 16th 
  • 16:30 – end of the exhibition day followed by a drink in the foyer of Hall 3*

Exclusively for members/exhibitors and their guests**:

  • 17:30 – Reception in the Conference Room of Hall 3 + welcome speech
  • 17:45 - Starter
  • 18:15 – Keynote by Liesbet Lagae (IMEC) - "Analyze the patient, engineer the therapy"
  • 18:45 -  Main course
  • 19:15 – Comedy by Christophe Deborsu & Annick De Wit
  • 20:00 – Dessert
  • 21:00 – Estimated end

*Exhibitor drink is accessible for all exhibitors 
** The participation fee for members/exhibitors and their guests at Connecting@LABORAMA is €60 p.p.
    Inscriptions are possible via the online exhibitor book. 

Keynote "Analyze the patient, engineer the therapy" door Liesbet Lagae, IMEC

The exponential growth of the semiconductor industry has shown value for consumers by increasing performance while scaling down the cost.  The result of that is the highest standard in precision and volume production of nanoelectronics based chip and sensor solutions.  Over the past 10 years,  Imec has used their experience in semiconductor process and design technologies for building out a health oriented activity that uses single use silicon biochips and microfluidics for DNA sequencing,  cell sorting,   DNA synthesis,   single cell gene editing and biosensing.    

These chip solutions have until now mainly served the diagnostic market.   But we need to go further,   similar technology building blocks can solve challenges in personalized healthcare by following trajectories of individual patients and by adapting the therapies.   The latest generation of therapies uses not only individual information from the patient,  but also patient material such as immune cells from the patient,  to build powerful new types of personalized treatments.  These innovative therapies come with very new challenges in relation to cost,  logistics and quality,  and todays lab infrastructure and healthcare system is not adapted for this.  We will explain how chip miniaturization can help to overcome important challenges along the healthcare cycle in order to give patient access to affordable,  more personalized and adapted treatments and save lives. 

Liesbet Lagae - Bio 

Liesbet Lagae, Ms. E. E., Phd, is IMEC fellow and currently program director of IMEC Life sciences.  In this role,  Liesbet is the scientific leader of a multidisciplinary team of > 50 researchers working on miniaturization of biochips, microfluidics and integration of bio-assays.  By leveraging those chip-based sensor solutions, she builds the tools for next generation sequencing, cytometry, cell sorting,  genomics, implantables and bioreactors. 

Liesbet Lagae (born 1975, Leuven, Belgium) received her PhD degree from the KU Leuven, Belgium for her work on Magnetic Random Access Memories in 2003.  She has pioneered life science technologies based on silicon based biochips at IMEC, Belgium.  She created a successfully growing business line how smart silicon biochips could be tailored to the needs of our customers in the medical community.   She was appointed as a KULeuven part time professor in nanobiophysics as a consequence of these early-carreer achievements. 

Liesbet has (co-) authored more than  300 publications. She holds 16 patents in the field.   She coordinated several EU and regional projects. She holds a prestigious ERC Consolidator Grant that deals with an innovative cell sorter-on-chip technology. She is or has been promotor of > 20 PhD students.